Abstract
BackgroundThere have been inconsistent results from case-control studies assessing the association of the PON1 Q192R polymorphism with coronary heart disease (CHD). Most studies have included predominantly men and the association in women is unclear. Since lipid levels vary between the sexes the antioxidant effect of PON1 and any genes associated with it may also vary by sex. We have examined the association of the PON1 Q192R polymorphism with CHD in a large cohort of British women and combined the results from our cohort study with those from all other published studies.ResultsThe distribution of genotypes was the same among women with CHD and those without disease. The odds ratio (95% confidence interval) of having CHD comparing those with either the QR or RR genotype to those with QQ genotype (dominant model of association) was 1.03 (0.89, 1.21) and the per allele odds ratio was 0.98 (0.95, 1.01). In a meta-analysis of this and 38 other published studies (10,738 cases and 17,068 controls) the pooled odds ratio for the dominant effect was 1.14 (1.08, 1.20) and for the per allele effect was 1.10 (1.06, 1.13). There was evidence of small study bias in the meta-analyses and the dominant effect among those studies with 500 or more cases was 1.05 (0.96, 1.15). Ethnicity and reporting of whether the genotyping was done blind to the participants clinical status also contributed to heterogeneity between studies, but there was no difference in effect between studies with 50% or more women compared to those with fewer women and no difference between studies of healthy populations compared to those at high risk (with diabetes, renal disease of familial hypercholesterolaemia).ConclusionThere is no robust evidence that the PON1 Q192R polymorphism is associated with CHD risk in Caucasian women or men.
Highlights
There have been inconsistent results from case-control studies assessing the association of the PON1 Q192R polymorphism with coronary heart disease (CHD)
The association of PON1 Q192R polymorphism with coronary heart disease in the British Women's Heart and Health Study Table 1 shows the characteristics of the study population by genotype
Genotype was not associated with CHD, obesity, insulin resistance, diabetes, dyslipidaemia, socioeconomic position or smoking
Summary
There have been inconsistent results from case-control studies assessing the association of the PON1 Q192R polymorphism with coronary heart disease (CHD). The antioxidant effect of HDLc is determined by its enzymes, in particular paraoxonase 1 (PON1), which catalyzes the hydrolysis of lipid peroxides, as well as being a potent hydroliser of a number of other substrates, including the active metabolites of organophosphates [5,6,7,8]. These findings have led to the suggestion that PON1 activity has a role in susceptibility to atherosclerotic disease [5,9]. It has been shown that the R alloenzyme confers least ability of HDLc to prevent oxidation of LDLc, mediated through the level of PON1 enzyme activity [12]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have